Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
4.410
-0.120 (-2.65%)
At close: Dec 20, 2024, 4:00 PM
4.130
-0.280 (-6.35%)
After-hours: Dec 20, 2024, 4:33 PM EST
Aptevo Therapeutics Employees
Aptevo Therapeutics had 40 employees as of December 31, 2023. The number of employees decreased by 5 or -11.11% compared to the previous year.
Employees
40
Change (1Y)
-5
Growth (1Y)
-11.11%
Revenue / Employee
n/a
Profits / Employee
-$593,025
Market Cap
2.21M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Venus Concept | 304 |
Helius Medical Technologies | 22 |
Biodexa Pharmaceuticals | 21 |
Cyclacel Pharmaceuticals | 12 |
Bluejay Diagnostics | 10 |
TransCode Therapeutics | 10 |
Shuttle Pharmaceuticals Holdings | 8 |
Dermata Therapeutics | 8 |
APVO News
- 9 days ago - Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds - Accesswire
- 9 days ago - 100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial - Accesswire
- 17 days ago - Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects - Accesswire
- 22 days ago - Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan - Accesswire
- 25 days ago - Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation - Accesswire
- 4 weeks ago - Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm - Accesswire
- 4 weeks ago - First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies - Accesswire
- 5 weeks ago - First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial - Accesswire